AR 100 - Arjil Pharmaceuticals
Alternative Names: AR100 - Arjil Pharmaceuticals; AR100DP1Latest Information Update: 28 Feb 2024
At a glance
- Originator Industrial Technology Research Institute
- Developer Arjil Pharmaceuticals
- Class Anti-inflammatories; Antigouts; Antipsoriatics; Antirheumatics; Herbal medicines; Skin disorder therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Atopic dermatitis
- No development reported Contact dermatitis; Gouty arthritis; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for research development in Contact-dermatitis in Taiwan (Topical)
- 28 Feb 2024 No recent reports of development identified for research development in Gouty arthritis in Taiwan (Topical)
- 28 Feb 2024 No recent reports of development identified for research development in Psoriasis in Taiwan (Topical)